[Newsmp] The amount of cash equivalents of listed pharmaceutical companies decreased slightly in the first quarter.
Among them, Dong-A ST rose to the KRW 200 billion mark, surpassing Yuhan Corporation, which retreated from KRW 200 billion.
Newsmp compiled the cash & cash equivalent of the 64 listed pharmaceutical companies whose closing accounts are in NovemberㆍDecember and found that the total was KRW 2.2028 trillion, down KRW 156.3 billion from the end of last year.
Of the 64 companies, more than half of 36 companies had their cash equivalents smaller than at the end of the previous year, and 28 expanded during the same period.
Yuhan Corporation, which had the largest amount of cash equivalents among listed pharmaceutical companies at the end of last year, decreased by KRW 71.4 billion, the largest drop.
The cash equivalents of 12 companies have shrunk by more than KRW 10 billion. GC Pharma’s cash equivalents declined by more than KRW 60 billion, Daewon Pharmaceutical KRW 32.2 billion, Chong Kun Dang Pharmaceutical KRW 29.1 billion, Reyon Pharmaceutical KRW 28.4 billion, Celltrion Pharm KRW 28 billion, Boryung Pharmaceutical KRW 23.9 billion, Huons KRW 22.5 billion, Aprogen Pharmaceuticals KRW 15.8 billion, DongKook Pharmaceutical KRW 14.5 billion, and Korea United Pharmaceutical KRW 13.2 billion.
On the other hand, during the same period, HK inno.N’s cash equivalents increased by KRW 65.5 billion, Hanmi Pharmaceutical by KRW 29.6 billion, Kyung Nam Pharm by KRW 23.7 billion, and Daewoong Pharmaceutical by KRW 20 billion.
Moreover, 12 companies saw an increase of more than KRW 10 billion, including PharmGen Science KRW 17.8 billion, Korea Arlico Pharm KRW 14.5 billion, Dongwha Pharm KRW 13 billion, CMG Pharmaceutical KRW 11.9 billion, Samjin Pharmaceutical KRW 11.5 billion, Dong-A ST KRW 11.3 billion, Bukwang Pharmaceutical KRW 10.4 billion, and Samil Pharmaceutical KRW 10.1 billion.
In the meantime, Dong-A ST’s cash equivalents amounted to KRW 201.3 billion, taking the lead among 64 companies, followed by Yuhan Corporation with KRW 160.4 billion.
HK inno.N surpassed KRW 150 billion with KRW 152.3 billion, and Boryung Pharmaceutical maintained the KRW 100 billion mark with KRW 121.8 billion, while Chong Kun Dang Pharmaceutical and Ildong Pharmaceutical pulled back from KRW 100 billion with KRW 99.8 billion and KRW 90.3 billion.
In addition, Daihan Pharmaceutical had KRW 86.1 billion, Dongwha Pharm KRW 68.4 billion, DongKook Pharmaceutical KRW 64.1 billion, Bukwang Pharmaceutical KRW 61.8 billion, Korea Pharmacy KRW 56.2 billion, Whanin Pharmaceutical KRW 54.6 billion, Daewoong Pharmaceutical KRW 53.1 billion, Celltrion Pharm KRW 52.1 billion, and PharmGen Science KRW 51.3 billion, and a total of 15 companies’ cash equivalents exceeded KRW 50 billion.
